Oxygen Biotherapeutics Announces Fiscal Year 2014 Financial Results
Wall Street Journal
… year, including proceeds from the March 2014 $59.8 million public offering of Common Stock; proceeds from the July 2013 $5.4 million public offering of Series C Preferred Stock and Warrants, and the exercise of certain outstanding warrants of $7.0 …
After subscribing to the service (All Levels) this menu will become active to direct you to member database locations and weekly audio recordings. Please refresh the page if you have subscribed and are still seeing this message.